SCINAI IMMUNOTHERAPEUTICS LTD. Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of ILS 506.00 thousand for the 12-month period ending 2021-12-31, per its 20-F filed 2022-03-28.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2022-03-28
- SCINAI IMMUNOTHERAPEUTICS LTD. increase decrease through financing cash flows liabilities arising from financing activities for the quarter ending 2020-12-31 was 1.34M ILS, a 91.19% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. increase decrease through financing cash flows liabilities arising from financing activities for the quarter ending 2020-09-30 was -212.00K ILS.
- SCINAI IMMUNOTHERAPEUTICS LTD. increase decrease through financing cash flows liabilities arising from financing activities for the quarter ending 2019-12-31 was 15.24M ILS.
- SCINAI IMMUNOTHERAPEUTICS LTD. increase decrease through financing cash flows liabilities arising from financing activities for the quarter ending 2019-09-30 was -167.00K ILS.
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 3 month | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 6 month | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 9 month | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | 506.00K ILS 20-F · filed 2022-03-28 | ||||
| 2020-12-31 | 1.34M ILS derived: 20-F 12 month − 6-K 9 month · filed 2022-03-28 | 1.13M ILS derived: sum of 2 quarters · filed 2022-03-28 | 761.00K ILS 20-F · filed 2022-03-28 | -761.00K ILS 20-F · filed 2021-05-13 | |
| 2020-09-30 | -212.00K ILS derived: 6-K 9 month − 6-K 6 month · filed 2021-01-28 | -582.00K ILS 6-K · filed 2021-01-28 | |||
| 2020-06-30 | -370.00K ILS 6-K · filed 2020-10-02 | ||||
| 2019-12-31 | 15.24M ILS derived: 20-F 12 month − 6-K 9 month · filed 2021-05-13 | 15.08M ILS derived: sum of 2 quarters · filed 2021-05-13 | 14.76M ILS 20-F · filed 2021-05-13 | ||
| 2019-09-30 | -167.00K ILS derived: 6-K 9 month − 6-K 6 month · filed 2021-01-28 | -489.00K ILS 6-K · filed 2021-01-28 | |||
| 2019-06-30 | -322.00K ILS 6-K · filed 2020-10-02 | ||||
| 2018-12-31 | 84.32M ILS 20-F · filed 2020-06-12 |